Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects

Clinical Hemorheology and Microcirculation

Volumn 40, Issue 2, 2008, Pages 79-87

  Vayá, Amparo ^a   Santaolaria, Marisa ^a   Micó, Luisa ^a   Calvo, Javier ^b   Oropesa, Roberto ^b   Villa, Piedad ^a   Todoli, Jose ^a   Simó, María ^a   Corella, Dolores ^c   Ricart, Jose M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Acquired thrombophilic defects; Inherited thrombophilic defects; Systemic lupus erythematosus; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LUPUS ANTICOAGULANT; PROTHROMBIN;

ADULT; ANTIBODY TITER; ANTITHROMBIN DEFICIENCY; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; BLOOD PROTEINS; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; THROMBOSIS;

EID: 57049159319     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: 10.3233/CH-2008-1117     Document Type: Article

References (33)

1. K. Qushmaq, J. Esdaile and D.V. Devine, Thrombosis in systemic lupus erythematosus: the role of antiphospholipid antibody, Arthrit. Care Res. 12 (1999), 212-219.
2. J.F. Tomas, I. Alberca, M.D. Tabernero, M. Cordero, J. Del Pino-Montes and V. Vicente, Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus, J. Rheumatol. 25 (1998), 57-62.
3. D. Barcat, V. Guerin, A. Ryman, J. Constans, J.P. Vernhes, C. Vergnes, F. Bonnet, X. Delbrel, P. Morlat, M. Longy-Boursier and C. Conri, Thrombophilia and thrombosis in systemic lupus erythematosus: a case-control study, Ann. Rheum. Dis. 62 (2003), 1016-1017.
4. J.L. Brouwer, M. Bijl, N.J. Veeger, H.C. Kluin-Neleman and J. van der Meer, The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus, Blood 104 (2004), 143-148.
5. A. Afeltra, M. Vadacca, L. Conti, S. Galluzzo, A.P. Mitterhofer, G.M. Ferri, F. Del Porto, D. Caccavo, G.M. Gandolfo and A. Amoroso, Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors, Arthrit. Rheum. 53 (2005), 452-459.
6. F. Martínez, M.J. Forner, M. Ruano, N. Abdilla, R. Oltra and M.J. García-Fuster, Factores relacionados con el riesgo de trombosis en pacientes con lupus y positividad para anticuerpos antifosfolipídicos, Med. Clin. 127 (2006), 405-409.
7. A. Martinez-Berriotxoa, G. Ruiz-Irastorza, M.V. Egurbide, M. Rueda and C. Aguirre, Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus, Lupus 13 (2004), 927-933.
8. T.M. Refai, I.H. Al-Salem, D. Nkansa-Dwamena and M.H. Al-Salem, Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients, Clin. Rheumatol. 21 (2002), 457-461.
9. M. Galli, D. Luciani, G. Bertolini and T. Barbui, Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome, Blood 102 (2003), 2717-2723.
10. E.Y. Lee, C.K. Lee, T.H. Lee, S.M. Chung, S.H. Kim, Y.S. Cho, B. Yoo and H.B. Moon, Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis?, Thromb. Res. 111 (2003), 29-32.
11. F.R. Rosendaal, Venous thrombosis: a multicausal disease, Lancet 353 (1999), 1167-1173.
12. R. Fijnheer, D.A. Horbach, R.C. Donders, H. Vile, E. von Oort, H.K. Nieuwenhuis, F.H. Gmelig-Meijling, P.G. de Groot and R.H. Derksen, Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus, Thromb. Haemost. 76 (1996), 514-517.
13. F.R. Rosendaal, C.J. Doggen, A. Zivelin, V.R. Arruda, M. Aiach, D.S. Siscovick, A. Hillarp, H.H. Watzke, F. Bernardi, A.M. Cumming, F.E. Preston and P.H. Reitsma, Geographic distribution of the 20210 G to A prothrombin variant, Thromb. Haemost. 79 (1998), 706-708.
14. E.M. Tan, A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Rothfield, J.G. Schaller, N. Talal and R.J. Winchester, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthrit. Rheum. 25 (1982), 1271-1277.
15. C. Bombardier, D.D. Gladman, M.B. Urowitz, D. Caron and C.H. Chang, Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE, Arthrit. Rheum. 35 (1992), 630-640.
16. S. Gandrille, M. Alhenc-Gelas and M. Aiach, A rapid screening method for the factor V Arg506→Gln mutation, Blood Coagul. Fibrinol. 6 (1995), 245-248.
17. S.R. Poort, F.R. Rosendaal, P.H. Reitsma and R.M. Bertina, A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood 88 (1996), 3698-3703.
18. A.A. Long, J.S. Ginsberg, P. Brill-Edwards, M. Johnston, C. Turner and J.A. Denburg, The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study, Thromb. Haemost. 66 (1991), 520-524.
19. E. Somers, L.S. Magder and M. Petri, Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus, J. Rheumatol. 29 (2002), 2531-2536.
20. G. Finazzi, V. Brancaccio, M. Moia, N. Ciaverella, M.G. Mazzucconi, P.C. Schinco, M. Ruggeri, E.M. Pogliani, G. Gamba, E. Rossi, F. Baudo, C. Manotti, A. D'Angelo, G. Palareti, V. De Stefano, M. Berrettini and T. Barbui, Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry, Am. J. Med. 100 (1996), 530-536.
21. C. Neville, J. Rauch, J. Kassis, S. Solymoss, L. Joseph, P. Belisle, R. Subang, E.R. Chang and P.R. Fortin, The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-beta2-glycoprotein I antibodies, Rheumatology (Oxford) 45 (2006), 1116-1120.
22. M. Hudson, A.L. Herr, J. Rauch, C. Neville, E. Chang, R. Ibrahim, C. Seguin, J. Kassis, L. Busque and P.R. Fortin, The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies, J. Rheumatol. 30 (2003), 2385-2391.
23. P. Von Landenberg, J. Scholmerich, J. von Kempis and K.J. Lackner, The combination of different antiphospholipid antibody subgroups predictor for thrombosis. A retrospective study from a single center, Immunobiology 207 (2003), 65-71.
24. P.R. Fortin, J. Kassis, C. Neville et al., The presence of antiphospholipid antibody predicts new thrombosis at three years in a high-risk population, Arthrit. Rheum. 48(Suppl. 9) (2003), S364.
25. M. Torresan, T.F. Machado, L.H. Siquiera, M.C. Ozelo, V.R. Arruda and J.M. Annichino-Bizzacchi, The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis, Blood Coagul. Fibrinol. 11 (2000), 679-682.
26. R. Topaloglu, C. Akierli, A. Bakkaloglu, O. Aydintug, S. Ozen, N. Besbas and T. Ozcelik, Survey of factor V Leiden and prothrombin gene mutations in systemic lupus erythematosus, Clin. Rheumatol. 20 (2001), 259-261.
27. P.A. Merkel, Y. Chang, S.S. Pierangeli, K. Convery, E.N. Harris and R.P. Polisson, The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases, Am. J. Med. 101 (1996), 576-583.
28. P.E. Love and S.A. Santoro, Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance, Ann. Intern. Med. 112 (1990), 682-698.
29. R. Cervera, M.A. Khamashta, J. Font, G.D. Sebastiani, A. Gil, P. Lavilla, I. Doménech, A.O. Aydintug, A. Jedryka-Goral, E. de Ramon et al., Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus, Medicine (Baltimore) 72 (1993), 113-124.
30. J.D. Oosting, R.H. Derksen, I.W. Bobbink, T.M. Hackeng, B.N. Bouma and P.G. de Groot, Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?, Blood 81 (1993), 2618-2625.
31. N. Regeczy, G. Lakos, I. Balogh, E. Ajzner, E. Kiss and G. Szegedi, The Leiden mutation of coagulation factor V in Hungarian SLE patients, Clin. Appl. Thromb. Hemost. 6 (2000), 41-45.
32. J.C. Souto, I. Coll, D. Llobet, E. del Rio, A. Oliver, J. Mateo, M. Borrell and J. Fontcuberta, The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population, Thromb. Haemost. 80 (1998), 366-369.
33. A. Vayá, Y. Mira, J. Mateo, C. Falco, P. Villa, A. Estellés, D. Corella, J. Fontcuberta and J. Aznar, Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk, Thromb. Haemost. 89 (2003), 452-457.